Efdoralprin alfa

Protein / enzyme therapeutic

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

This drug's own stage for Alpha-1 Antitrypsin Deficiency: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Efdoralprin Alfa: this drugStage not on recordProtein / enzyme therapeuticAlpha-1 antitrypsin (AAT)not yet gradedNo reviewed efficacy summary in this indication
FazirsiranPhase 3RNA / oligonucleotideSERPINA1not yet gradedNo reviewed efficacy summary in this indication
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
BEAM-302Phase 1/2Gene therapy / editingSERPINA1 PiZ mutation (E342K)not yet gradedNo reviewed efficacy summary in this indication
TSRA-196Phase 1/2Gene therapy / editingSERPINA1not yet gradedNo reviewed efficacy summary in this indication
WVE-006Phase 1/2RNA / oligonucleotideSERPINA1 Z-allele mRNA (ADAR-mediated editing)not yet gradedNo reviewed efficacy summary in this indication
KB408Phase 1Gene therapy / editingSERPINA1 (alpha-1 antitrypsin; gene replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.